Trials / Completed
CompletedNCT02679196
The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Karus Therapeutics Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multiple ascending dose study to evaluate safety/tolerability, pharmacokinetic and pharmacodynamics effects of KA2237 (PI3 Kinase p110β/δ Inhibitor) in patients with B Cell Lymphoma and determine the maximum tolerated dose (MTD) in Part I of the study. In Part II, patients with B cell lymphoma will be treated with KA2237 at the MTD to evaluate safety and efficacy in the patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KA2237 | PI3 Kinase p110β/δ inhibitor |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-12-24
- Completion
- 2018-12-24
- First posted
- 2016-02-10
- Last updated
- 2019-02-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02679196. Inclusion in this directory is not an endorsement.